COGT insider trading
NasdaqGS HealthcareCogent Biosciences, Inc.: insider trade history from SEC Form 4 filings.
About Cogent Biosciences, Inc.
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.
Company website: www.cogentbio.com
COGT insider activity at a glance
FilingIQ tracks 204 insider transactions for COGT in filings since Oct 20, 2016. The most recent transaction is dated Aug 27, 2026.
Across the full history, 72 open-market purchases
and 41 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on COGT insider trades is 52.3/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Latest COGT Form 4 filings
Most recent disclosures. Sign up to filter by score, transaction code, or insider role.
Other Healthcare tickers with recent insider activity
Frequently asked
- How many insider trades does FilingIQ track for COGT?
- FilingIQ tracks 204 Form 4 insider transactions for COGT (Cogent Biosciences, Inc.), covering filings from Oct 20, 2016 onwards. 4 of those are dated within the last 90 days.
- Are COGT insiders net buyers or net sellers?
- Across the full Form 4 history for COGT, 72 transactions (35%) were open-market purchases and 41 (20%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does COGT insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ normalises insider identity across reporting variations and scores discretionary open-market purchases and sales on its multi-factor composite model.
- What sector is COGT in?
- Cogent Biosciences, Inc. (COGT) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $5.92B.
Methodology & sources
Every COGT insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.